Brainomix has partnered with the TIPAL trial group to run a sub-study that will assess the value of its e-Lung platform, an AI-powered image processing module.The TIPAL trial, a placebo-controlled, 52 week multi-centre study, is evaluating the impact of lansoprazole, a medication for treating indigestion, heartburn and acid reflux, on patients with idiopathic pulmonary fibrosis (IPF).Brainomix will be running a sub-study alongside the main study, to look at the value of its novel imaging biomarkers.The company’s technology includes a tool that standardises the quantification of lung fibrosis on high resolution CT scans in order to more accurately identify progressive fibrosis patients.

Brainomix已与TIPAL试验小组合作开展了一项子研究，该子研究将评估其电子肺平台（一种由AI驱动的图像处理模块）的价值。TIPAL试验是一项安慰剂对照，为期52周的多中心研究，正在评估兰索拉唑（一种治疗消化不良，胃灼热和酸反流的药物）对特发性肺纤维化（IPF）患者的影响.Brainomix将在与主要研究一起进行子研究，看看其新型成像生物标志物的价值。该公司的技术包括一种工具，可以在高分辨率CT扫描中标准化肺纤维化的量化，以便更准确地识别进行性纤维化患者。

The AI platform uses a novel imaging biomarker, the weighted reticulovascular (WRV) score, to quantify the extent of the lung impacted by reticulovascular abnormalities.The aim of the sub-study is to determine the difference in change between baseline and 12 months post-randomisation, in WRV score between treatment with lansoprazole and placebo.Dr Peter George, senior medical director at Brainomix and clinical lead for ILD at Royal Brompton Hospital in London, said: “We are excited to have the opportunity to collaborate with the TIPAL study group, and to incorporate our pioneering AI technology into a prospective trial to help assess the efficacy of lansoprazole in IPF patients.“We are highly motivated by the potential to harness our technology in a way that helps to speed up clinical trials, identify more effective drugs, and improve the lives of IPF patients.”Professor Andrew Wilson, TIPAL chief investigator, added: “It is great to have the chance to incorporate the cutting-edge CT scanning technology developed by Brainomix into the TIPAL study.

AI平台使用新型成像生物标志物，加权网状血管（WRV）评分，以量化受网状血管异常影响的肺的程度。该子研究的目的是确定基线和随机分组后12个月之间WRV评分与兰索拉唑和安慰剂治疗之间的变化差异。Brainomix的高级医疗主任Peter George博士和伦敦皇家布朗普顿医院ILD的临床负责人，说：“我们很高兴有机会与TIPAL研究小组合作，并将我们开创性的AI技术纳入前瞻性试验，以帮助评估兰索拉唑在IPF患者中的疗效。“我们非常有动力以有助于加快临床试验，确定更有效的药物并改善IPF患者生活的方式利用我们的技术。”TIPAL首席研究员Andrew Wilson教授补充说：“将Brainomix开发的尖端CT扫描技术纳入TIPAL研究的机会非常大。

Not only will this venture tell whether l.

这项冒险不仅会告诉l。